ASCRS 2023: Laser scleral microporation from ACE Vision Group

Mitchell Jackson, MD, discussed laser scleral microporation from ACE Vision Group at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Mitchell Jackson, MD:

Hi, I'm Dr. Mitchell Jackson. I'm founder and CEO of Jacksoneye in Lake Villa, Illinois, and today we're going to talk about laser scleral microporation from ACE Vision Group. This technology is a treatment for the aging eye. We actually put micropores in the sclera in four quadrants and we do this at the early presbyopia age between like 40 and 55 [if] you haven't developed a cataract yet. We're trying to prevent the aging process from happening. And if it's already happened, we're trying to get the vision recovered from the aging process. You no longer have to wear reading glasses, at least for your cell phone, iPad, laptop, or most of our activities of daily living at near vision.

The difference with this technology versus others... The data so far out to 2 years in our OUS data shows that it's stable out to 2 years to a level that equates to what we see with our premium advanced IOLs, at least J3 or better for intermediate and near vision and with no loss of distance vision uncorrected.

The great thing about [it is] it's extraocular. It's not intraocular. So you have none of the risks of an intracular procedure. It's done on the sclera, not done in the eye or on the cornea or in the visual axis. There's no potential sight-threatening adverse events such as glare or halo because we're not in the visual axis. We're outside the visual axis. It doesn't affect anything for future cataract surgery, because eventually you're gonna get a cataract and need cataract surgery, so it will not affect keratometry or biometry. IOL calculations will not have to be altered if you do this procedure at the early presbyopia age. So those are the big differences. Stay tuned for laser scleral microporation.